Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Tamarisk Technologies, LLC has filed an application for exemption of Phase I and 2 oral insulin clinical trials and has asked the FDA to allow them to enter Phase 3 trials with their oral formulation of insulin. Christopher LaPoma, VP of Operations and Business Relations sounded optimistic about the requested exemptions while noting extensive pre-existing pharmacological data within the company?s possession.
Tamarisk Technologies, LLC who revealed the end of a decade of carefully shrouded research with their successful oral administration of insulin, has made headlines again today with their announcement of their intent to complete phase 3 clinical trials by the end of 2012.
http://www.prweb.com/releases/prweb2012/6/prweb9583694.htm
Tamarisk Technologies, LLC who revealed the end of a decade of carefully shrouded research with their successful oral administration of insulin, has made headlines again today with their announcement of their intent to complete phase 3 clinical trials by the end of 2012.
http://www.prweb.com/releases/prweb2012/6/prweb9583694.htm